Related Experiment Video
Updated: Jul 15, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
[Thrombotic microangiopathies. Incidence, pathogenesis, diagnosis, treatment and prognosis]
M Bahloul1, H Dammak, H Kallel
1Service de réanimation médicale, CHU Habib-Bourguiba, route El-Ain-Km 1, 3029 Sfax, Tunisie. bahloulmab@yahoo.fr
Introduction:
The objective of this work was to review current data about the pathophysiology, clinical features, and treatment of thrombotic microangiopathies.
Current Knowledge:
Thrombotic microangiopathies are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes. In thrombotic thrombocytopenic purpura, systemic microvascular aggregation of platelets causes ischemia in the brain and other organs. In the hemolytic-uremic syndrome, platelet-fibrin thrombi occlude predominantly the renal circulation. Thrombotic microangiopathy is a rare disorder whose varied clinical manifestations result from the formation of platelet-rich thrombi within the microvasculature and consequent tissue ischemia. The clinical features are acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. This diagnosis is of considerable importance because of the possible fulminant clinical course. Some atypical forms may be unrecognized. Plasma exchange is the current reference treatment of thrombotic thrombocytopenic purpura. However, in the light of recent publications, either infusions of concentrates of purified enzyme or more intensive immunosuppressive therapy would be more specific.
Insights
Thrombotic microangiopathies involve platelet aggregation, causing organ damage. Current treatments like plasma exchange may be improved by enzyme infusions or immunosuppression for better outcomes.
Area of Science:
- Hematology
- Nephrology
- Pathophysiology
Context:
- Thrombotic microangiopathies (TMAs) are rare vascular disorders.
- TMAs involve platelet aggregation, thrombocytopenia, and red blood cell injury.
- Key TMAs include thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS).
Purpose:
- To review current data on TMA pathophysiology, clinical features, and treatment.
- To highlight the diagnostic importance and potential severity of TMAs.
- To discuss evolving therapeutic strategies beyond plasma exchange.
Summary:
- TMAs are characterized by microvascular thrombosis leading to organ ischemia.
- Clinical presentations include renal failure, hemolytic anemia, and thrombocytopenia.
- Plasma exchange is standard for TTP, but enzyme infusions or immunosuppression show promise.
Impact:
- Enhanced understanding of TMA pathogenesis and clinical spectrum.
- Informed clinical decision-making for TMA diagnosis and management.
- Potential for improved patient outcomes with novel therapeutic approaches.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Ischemic Stroke ll: Pathophysiology

